AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TELIX PHARMACEUTICALS LTD

27.990

+0.8603.17%

Volume:1.30M

Turnover:36.07M

Market Cap:9.46B

PE:193.57

High:28.190

Open:27.610

Low:27.300

Close:27.130

Loading ...

Overview Company News Filings

BRIEF-Illuccix Prostate Cancer Psma-Pet Imaging Agent Approved In Finland

Illuccix Prostate Cancer Psma-Pet Imaging Agent Approved in Finland

THOMSON REUTERS

Brokers tip 4 ASX 200 healthcare shares to buy now

BUZZ-ASX-listed Telix Pharmaceuticals rises; Morningstar expects regulatory approval for Pixclara

Telix Pharmaceuticals Secures Marketing Authorization for Prostate Cancer Imaging Agent in France

MT Newswires Live

Telix's Illuccix Psma-Pet Imaging Agent Approved in France

THOMSON REUTERS

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

BUZZ-Morningstar expects FDA nod for Telix Pharmaceuticals' Pixclara to be delayed, not denied

5 things to watch on the ASX 200 on Tuesday

BUZZ-U.S. STOCKS ON THE MOVE-Marriott, Wells Fargo, Insulet

BUZZ-Telix Pharma dips as FDA rejects brain cancer imaging agent

Australian Shares Rise on Tech Rally; Telix Faces US FDA Setback

MT Newswires Live

BUZZ-ASX-listed Telix Pharmaceuticals stock tumbles after FDA denies Pixclara approval

BRIEF-Telix Pharmaceuticals Says FDA Requires Additional Clinical Evidence For Tlx101-Cdx Approval

Telix Pharmaceuticals Says US FDA Ruled New Drug Application for Brain Cancer Imaging Agent 'Cannot be Approved in Current Form'; Shares Down 7%

MT Newswires Live

Stock Track | Telix Pharmaceuticals Plunges 5.50% as FDA Demands More Clinical Evidence for TLX101-CDX

Telix Pharmaceuticals Ltd - FDA Requires Additional Clinical Evidence for Tlx101-Cdx Approval

THOMSON REUTERS

Telix: A masterclass in what this game is all about

Why Orthocell, Paladin Energy, Telix, and Woodside shares are racing higher today

Why is the ASX 200 roaring higher today?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TLX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":27.99,"timestamp":1746079920000,"preClose":27.13,"halted":0,"volume":1295208,"delay":0,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":274906865,"shares":337878497,"eps":0.1446,"marketStatus":"Not Yet Opened","change":0.86,"latestTime":"05-01 16:12:00 AEST","open":27.61,"high":28.19,"low":27.3,"amount":36071465,"amplitude":0.032805,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.1446,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746144000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":27.13,"openAndCloseTimeList":[[1746057600000,1746079200000]],"volumeRatio":0.577283019484106,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":274906865,"roa":"5.33%","roe":"13.92%","lyrEps":0.150709,"volumeRatio":0.577283019484106,"shares":337878497,"dividePrice":0,"high":28.19,"amplitude":0.032805,"preClose":27.13,"low":27.3,"week52Low":14.42,"pbRate":"16.64","psRate":"12.07","week52High":31.97,"institutionHeld":0,"latestPrice":27.99,"eps":0.1446,"divideRate":0,"volume":1295208,"delay":0,"ttmEps":0.1446,"open":27.61,"prevYearClose":24.61,"prevWeekClose":28.56,"prevMonthClose":27.13,"prevQuarterClose":26.52,"fiveDayClose":28.32,"twentyDayClose":26.52,"sixtyDayClose":28.68},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531777462","title":"BRIEF-Illuccix Prostate Cancer Psma-Pet Imaging Agent Approved In Finland","url":"https://stock-news.laohu8.com/highlight/detail?id=2531777462","media":"Reuters","labels":["productRelease","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531777462?lang=en_us&edition=fundamental","pubTime":"2025-04-30 14:58","pubTimestamp":1745996297,"startTime":"0","endTime":"0","summary":"BRIEF-Illuccix Prostate Cancer Psma-Pet Imaging Agent Approved In FinlandApril 30 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX:ILLUCCIX PROSTATE CANCER PSMA-PET IMAGING AGENT APPROVED IN FINLANDTELIX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA3XYBSM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-Illuccix Prostate Cancer Psma-Pet Imaging Agent Approved In Finland","news_tag":"productRelease,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2531771052","title":"Illuccix Prostate Cancer Psma-Pet Imaging Agent Approved in Finland","url":"https://stock-news.laohu8.com/highlight/detail?id=2531771052","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531771052?lang=en_us&edition=fundamental","pubTime":"2025-04-30 14:17","pubTimestamp":1745993864,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA3XYBSM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2531227449","title":"Brokers tip 4 ASX 200 healthcare shares to buy now","url":"https://stock-news.laohu8.com/highlight/detail?id=2531227449","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531227449?lang=en_us&edition=fundamental","pubTime":"2025-04-29 15:05","pubTimestamp":1745910347,"startTime":"0","endTime":"0","summary":"ASX 200 healthcare shares finished in the green on Tuesday, with the S&P/ASX 200 Health Care Index  lifting 0.61%.  Healthcare is seen as a defensive sector.  In today's turbulent market, perhaps you might be looking for buying opportunities?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/29/brokers-tip-4-asx-200-healthcare-shares-to-buy-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["RMD.AU","CSL.AU","BK7501","BK7067","BK7007","BK7508","BK7511","HLS.AU","BK7124","TLX.AU","BK7509"],"gpt_icon":0},{"id":"2531499872","title":"BUZZ-ASX-listed Telix Pharmaceuticals rises; Morningstar expects regulatory approval for Pixclara","url":"https://stock-news.laohu8.com/highlight/detail?id=2531499872","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531499872?lang=en_us&edition=fundamental","pubTime":"2025-04-29 12:15","pubTimestamp":1745900157,"startTime":"0","endTime":"0","summary":"BUZZ-ASX-listed Telix Pharmaceuticals rises; Morningstar expects regulatory approval for Pixclara Updates with share moves** Shares of Telix Pharmaceuticals TLX.AX rise 2.8% to A$27.44** Morningstar a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4N3R7088:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2531291299","title":"Telix Pharmaceuticals Secures Marketing Authorization for Prostate Cancer Imaging Agent in France","url":"https://stock-news.laohu8.com/highlight/detail?id=2531291299","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531291299?lang=en_us&edition=fundamental","pubTime":"2025-04-29 07:49","pubTimestamp":1745884196,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  received marketing authorization in France for Illuccix, its prostate cancer positron emission tomography  imaging agent, the company said in a statement Monday.Illucix is indicated in France for the detection and localization of prostate-specific membrane antigen-positive lesions in adults with prostate cancer, the statement said.The company is partnering with IRE Group subsidiary IRE ELiT to market and promote Illuccix in France, according to the statement.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","BK7067","PET.AU","BK4192","PET","BK7047","TLX"],"gpt_icon":0},{"id":"2531984952","title":"Telix's Illuccix Psma-Pet Imaging Agent Approved in France","url":"https://stock-news.laohu8.com/highlight/detail?id=2531984952","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531984952?lang=en_us&edition=fundamental","pubTime":"2025-04-29 06:30","pubTimestamp":1745879426,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nTUABX77NH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2531999262","title":"Telix's Illuccix PSMA-PET Imaging Agent Approved in France","url":"https://stock-news.laohu8.com/highlight/detail?id=2531999262","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531999262?lang=en_us&edition=fundamental","pubTime":"2025-04-29 06:30","pubTimestamp":1745879400,"startTime":"0","endTime":"0","summary":"New approval provides French hospitals and clinics with access to a provenPSMA-PET imaging agent. MELBOURNE, Australia, April 29, 2025  -- Telix Pharmaceuticals Limited  today announces that its prostate cancer PET1 imaging agent, Illuccix , has been granted marketing authorization in France by ANSM2 for the detection and localization of prostate-specific membrane antigen -positive lesions in adults with prostate cancer, a broad clinical label.Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane antigen -positive lesions with PET in adults with prostate cancer  in the following clinical settings:. Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer  for whom PSMA-targeted therapy is indicated.With its broad indication and ready-to-use formulation, Illuccix is designed to support healthcare providers in delivering efficient and reliable imaging. The approval comes as d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telixs-illuccix-psma-pet-imaging-223000028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","TLX.AU","ASX","DCP","PSA","BK4109","BK4205","BK4233","BK4528","BK4533","BK4526","BK4192","EEA","BK4139","BK4084","BK4213","BK4588","BK4144","TLX","CE","BK4217","UK","PET","BCR","BK4543","TGA","BK4141"],"gpt_icon":0},{"id":"2531155264","title":"BUZZ-Morningstar expects FDA nod for Telix Pharmaceuticals' Pixclara to be delayed, not denied","url":"https://stock-news.laohu8.com/highlight/detail?id=2531155264","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531155264?lang=en_us&edition=fundamental","pubTime":"2025-04-29 05:21","pubTimestamp":1745875276,"startTime":"0","endTime":"0","summary":"BUZZ-Morningstar expects FDA nod for Telix Pharmaceuticals' Pixclara to be delayed, not denied** Morningstar analysts expect Telix Pharmaceuticals TLX.AX to receive a delayed regulatory approval, inst","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nL4N3R61SW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2531295005","title":"5 things to watch on the ASX 200 on Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2531295005","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531295005?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:54","pubTimestamp":1745873649,"startTime":"0","endTime":"0","summary":"On Monday, theS&P/ASX 200 Index started the week in a positive fashion. The benchmark index rose 0.35% to 7,997.1 points. Will the market be able to build on this on Tuesday?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/29/5-things-to-watch-on-the-asx-200-on-tuesday-29-april-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK7507","EVN.AU","BK7506","LYC.AU","BK7104","XJO.AU","BK7095","STO.AU","TLX.AU","KAR.AU","BK7142","RRL.AU"],"gpt_icon":0},{"id":"2530231194","title":"BUZZ-U.S. STOCKS ON THE MOVE-Marriott, Wells Fargo, Insulet","url":"https://stock-news.laohu8.com/highlight/detail?id=2530231194","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530231194?lang=en_us&edition=fundamental","pubTime":"2025-04-28 23:51","pubTimestamp":1745855481,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Marriott, Wells Fargo, InsuletEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nL4N3R61IT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAR","WY","3NVD.UK","OPRA","LU2063271972.USD","NVDS.UK","NEM","NVD3.UK","SABR","SPCB","CGON","INTJ","SAG","TSYW.SI","VLRS","2NVD.UK","NVD2.UK","RBOT","BHVN","IE00B7SZLL34.SGD","WOLF","NVDX","DPZ","NVDY","TLX.AU","RVTY","PODD","NVDS","NVD","SPRBX","AMPY","SPRB","CNC","EAF","GLMD","NVIW.SI","MTD","SNVD.UK","SWTX","ADMA","NVDU","NVDD","AZUL","PLUG"],"gpt_icon":1},{"id":"2530159238","title":"BUZZ-Telix Pharma dips as FDA rejects brain cancer imaging agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2530159238","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530159238?lang=en_us&edition=fundamental","pubTime":"2025-04-28 22:49","pubTimestamp":1745851762,"startTime":"0","endTime":"0","summary":"BUZZ-Telix Pharma dips as FDA rejects brain cancer imaging agent** U.S.-listed shares of Australia's Telix Pharmaceuticals TLX.AX, TLX.O fall 7.8% to $17.35** Late on Sunday, co said the US FDA declined to approve its marketing application for Pixclara, an imaging agent for glioma brain cancer** TLX said FDA has requested additional clinical evidence to progress the application, stating that the application cannot be approved in its current form** An imaging agent is a substance used in medical scans to enhance the visibility of internal body structures** Co said it plans to request a hearing with the FDA to understand the decision and explore ways to supplement their application** The rejection does not affect the company's financial forecasts for 2025, co said** Including session move, stock up 8.4% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nL4N3R61FP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2530544555","title":"Australian Shares Rise on Tech Rally; Telix Faces US FDA Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2530544555","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530544555?lang=en_us&edition=fundamental","pubTime":"2025-04-28 14:40","pubTimestamp":1745822421,"startTime":"0","endTime":"0","summary":"Australian shares continued to rally on Monday, led by the information technology sector, with all but one sector trading in the green.The S&P/ASX 200 Index rose 28.90 points, or 0.36%, to 7,997.10.Th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DHG.AU","BK7039","BK7044","BK7503","TLX.AU","JHX.AU","XKO.AU","XAO.AU","BK7002","XJO.AU","BK7067","ASX.AU"],"gpt_icon":0},{"id":"2530963418","title":"BUZZ-ASX-listed Telix Pharmaceuticals stock tumbles after FDA denies Pixclara approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2530963418","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530963418?lang=en_us&edition=fundamental","pubTime":"2025-04-28 11:21","pubTimestamp":1745810462,"startTime":"0","endTime":"0","summary":"BUZZ-ASX-listed Telix Pharmaceuticals stock tumbles after FDA denies Pixclara approval** Shares of Telix Pharmaceuticals TLX.AX fall 6% to A$26.86, their lowest since April 14** Stock among the bigges","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nL4N3R6094:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2530496506","title":"BRIEF-Telix Pharmaceuticals Says FDA Requires Additional Clinical Evidence For Tlx101-Cdx Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2530496506","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530496506?lang=en_us&edition=fundamental","pubTime":"2025-04-28 09:34","pubTimestamp":1745804084,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Says FDA Requires Additional Clinical Evidence For Tlx101-Cdx ApprovalApril 28  - Telix Pharmaceuticals Ltd TLX.AX:FDA REQUIRES ADDITIONAL CLINICAL EVIDENCE FOR TLX101-CDX APPROVALFDA RAISES NO SAFETY CONCERNS FOR TLX101-CDXFurther company coverage: TLX.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nFWN3R408S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2530827498","title":"Telix Pharmaceuticals Says US FDA Ruled New Drug Application for Brain Cancer Imaging Agent 'Cannot be Approved in Current Form'; Shares Down 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530827498","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530827498?lang=en_us&edition=fundamental","pubTime":"2025-04-28 08:37","pubTimestamp":1745800678,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said the US Food and Drug Administration  ruled that its New Drug Application for TLX101-CDx, an investigational agent for the imaging of glioma, cannot be approved in its current form, according to a Monday filing with the Australian bourse.Glioma is a rare and life-threatening type of brain cancer.In its complete response letter, the FDA stated further confirmatory clinical evidence is necessary to proceed with the application, the filing said.The company plans to request a hearing with the FDA to review the basis for the decision, per the filing.Telix Pharmaceuticals shares were down 7% in morning trade on Monday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK7067","TLX.AU","TLX"],"gpt_icon":0},{"id":"1176893415","title":"Stock Track | Telix Pharmaceuticals Plunges 5.50% as FDA Demands More Clinical Evidence for TLX101-CDX","url":"https://stock-news.laohu8.com/highlight/detail?id=1176893415","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176893415?lang=en_us&edition=fundamental","pubTime":"2025-04-28 08:10","pubTimestamp":1745799019,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd  saw its stock price plummet by 5.50% in Monday's trading session following news that the U.S. Food and Drug Administration  is requiring additional clinical evidence for the approval of its TLX101-CDX product. This development has sparked concerns among investors about potential delays in the product's path to market.The FDA's request for more clinical data suggests that the current evidence provided by Telix Pharmaceuticals may not be sufficient to demonstrate the eff","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Telix Pharmaceuticals Plunges 5.50% as FDA Demands More Clinical Evidence for TLX101-CDX","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"gpt_icon":0},{"id":"2530563469","title":"Telix Pharmaceuticals Ltd - FDA Requires Additional Clinical Evidence for Tlx101-Cdx Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2530563469","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530563469?lang=en_us&edition=fundamental","pubTime":"2025-04-28 06:34","pubTimestamp":1745793254,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250427:nFWN3R408S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2530977299","title":"Telix: A masterclass in what this game is all about","url":"https://stock-news.laohu8.com/highlight/detail?id=2530977299","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530977299?lang=en_us&edition=fundamental","pubTime":"2025-04-25 04:16","pubTimestamp":1745525760,"startTime":"0","endTime":"0","summary":"Every now and again, an ASX company emerges that captures the hearts and minds of investors. It doesn't happen every year, but it certainly happens more often than you think. From Droneshield  to ProMedicus  to Supply Network , these companies have all produced total returns in excess of 700% over the last 5 years. The latest market darling is, of course, none other thanTelix Pharmaceuticals. Just 5 years ago, the company reported revenue of $3.5m and now its 2025 sales guidance is in excess of $1.2 billion , a phenomenal 343x increase!Its share price has done alright, just a lazy 25x increase over the same period. It's the stuff that dreams are made of, and it reminds us why we love this game of investing. Now, if you cut out the hype, there are actually important investing lessons to learn from Telix. Stay optimistic and always look forward Five years ago, we were in the midst of a pandemic, and the world was facing a lot of uncertainty. (Not much has changed!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/25/telix-a-masterclass-in-what-this-game-is-all-about/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7115","SNL.AU","DRO.AU","BK7086","FOMO","BK7094","PME.AU","TLX.AU","BK7067"],"gpt_icon":0},{"id":"2529290519","title":"Why Orthocell, Paladin Energy, Telix, and Woodside shares are racing higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2529290519","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529290519?lang=en_us&edition=fundamental","pubTime":"2025-04-23 10:39","pubTimestamp":1745375981,"startTime":"0","endTime":"0","summary":"In afternoon trade, theS&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1.6% to 7,942.8 points. Four ASX shares that are rising more","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/23/why-orthocell-paladin-energy-telix-and-woodside-shares-are-racing-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XJO.AU","BK7142","BK1258","WDS.AU","BK7145","BK7508","LHM.AU","PDN.AU","TLX.AU","BK7067","BK1229","00495","OCC.AU","BK7509","BK7083"],"gpt_icon":0},{"id":"2529544824","title":"Why is the ASX 200 roaring higher today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2529544824","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529544824?lang=en_us&edition=fundamental","pubTime":"2025-04-23 10:25","pubTimestamp":1745375105,"startTime":"0","endTime":"0","summary":"It's a great day on the S&P/ASX 200 Index  today. At the time of writing, the benchmark Aussie index is up 1.6% at 7,939.1 points. ASX 200 uranium stock Paladin Energy Ltd  is leading the charge, with shares up 21.6% following this morning's strong quarterly production update. As for the biggest company on the ASX, Commonwealth Bank of Australia  shares broke into new all-time high territory in earlier trade today at $168.70 each. Shares have since given back those gains to be down 0.8% at the time of writing. Meanwhile, the BHP Group Ltd  share price is up 3.0%, while shares in biotech giant CSL Ltd  are up 1.9%. So, why is the ASX having such a stellar run today?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/23/why-is-the-asx-200-roaring-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4527","TSYW.SI","3NVD.UK","NQmain","LU1861558580.USD","XJO.AU","SG9999004303.SGD","QID","LU2265009873.SGD","SQQQ","IE00BDCRKT87.USD","LU0238689110.USD","LU1674673428.USD",".IXIC","LU0048584097.USD","CSL.AU","NVD2.UK","LU2125909916.SGD","NVDS.UK","NVIW.SI","LU1935043023.USD","QLD","PDN.AU","USJW.SI","SNVD.UK","NVDS","NVD3.UK","2NVD.UK","MNQmain","LU0417517546.SGD","LU1989772923.USD","LU0823434740.USD","IE00BJLML261.HKD","TLX.AU","NVDD","TQQQ","BK4579","USAW.SI","CBA.AU","LU2552382058.USD","NVDY","PSQ","BHP.AU","NVDU"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null},{"date":"2024-08-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724284800000,"name":null,"time":"","dateTimestamp":1724248800000,"actualEps":null},{"date":"2024-02-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708556400000,"name":null,"time":"","dateTimestamp":1708520400000,"actualEps":null},{"date":"2023-10-18","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1697583600000,"name":null,"time":"","dateTimestamp":1697547600000,"actualEps":null},{"date":"2023-08-23","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1692748800000,"name":null,"time":"","dateTimestamp":1692712800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[]}}